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Ovarian Cancer
• Most lethal gynecological cancer.
• High-grade serous ovarian carcinoma (HGSOC) most common.
Exosomes
• Extracellular vesicles that contain macromolecular cargo – such
as nucleic acids, proteins, and lipids – that play a significant role
in intracellular communication and modifying the extracellular
microenvironment.
• Formed as intraluminal vesicles (ILVs) within multivesicular
bodies (MVBs) within the plasma membrane to be packaged and
sent for release in the extracellular space.
• Release mechanisms have a potential role in ovarian cancer cell
progression.
Tumor exosome inhibitors (TEXi1 and TEXi2)
• Have shown promise in inhibiting exosome release; however, the
mechanisms at which they do so are unknown.
INTRODUCTION
• Model systems: Healthy fallopian tube secretory epithelial cells
(FT33) as control, OVSAHO, MeSOV, OVCAR-3 and OVCAR-4
cancer cell lines (HGSOC) grown in exosome-free fetal bovine
serum containing media.
• MTS cell viability assay for IC50 determination.
• Treatments include dimethyl sulfoxide (DMSO) as control, MKT-
077, Nexinhib20, GW4869, TEXi1, or TEXi2 for 48 hours.
• Exosomes isolated using ultracentrifugation and filtration.
• Exosome protein markers confirmed through Western blotting.
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Results Summary
• Exosome secretion proteins detected in immunoblots.
• Exosome CD63 levels decreased in TEXi1 and TEXi2 in
OVCAR-3 and OVCAR-4 cell lines compared to solvent.
Limitations
• Low exosome concentrations loaded in Western blot.
• Time constraints.
Future Directions
• Treat OVCAR-4-CD63-GFP expressing cells with TEXi1
at IC50 and IC75 at fixed time points and image live cells
using fluorescent microscopy.
• Isolate exosomes from plasma samples from MeSOV
mouse model and perform Western blot to investigate
TEXi1 treatment in vivo.
• Treat cells at IC75 concentration.
Societal Impact
• Known mechanisms of action for TEXi1 and TEXi2 can
provide insight into developing new therapeutic agents for
ovarian cancer metastasis.
DISCUSSIONHypothesis
• TEXi1 and TEXi2 inhibit exosomes of ovarian cancer cells
through similar mechanisms of known exosome inhibitors.
Objective
• To investigate the exosome secretion inhibition mechanisms of
TEXi1 and TEXi2 compared to known exosome inhibitory drugs
(MKT-077, Nexinhib20, GW4869).
HYPOTHESIS & OBJECTIVE
Figure 1. Exosome secretion pathway
mechanisms. MVB biogenesis is governed
by endosomal sorting complexes required
for transport machinery (ESCRT)-
dependent and ESCRT-independent
pathways. ESCRT-independent pathways
involve the conversion of sphingolipids to
ceramide, that traffick the exosomes to be
released. Rab27A and Rab27B traffick the
exosomes to fuse with the membrane and
to be released in the extracellular space.
Exosomes may also fuse with the
lysosomes in ESCRT-dependent
mechanisms.
Exosome Inhibitors IC50 Determination using OVCAR-4-CD63-Nluc Model Nanoparticle Tracking Analysis
Figure 3. Exosome isolation methodology and Western blots of treated cells. A.
Schematic illustration of the exosome isolation. B. Western blots confirming presence of
ESCRT-dependent and ESCRT-independent proteins in whole cell lysates with added drug
treatments: TEXi1 (0.98 µM), MKT-077 (0.58 µM), Nexinhib20 (0.99 µM), and GW4869
(1.134 µM) . C. Exosome Western blots confirmation.
SIGNIFICANCE / IMPACT
• Preventing ovarian cancer metastasis in the tumor
microenvironment by using novel therapeutics to target and inhibit
exosome secretion.
Exosome Isolation & Confirmation
Figure 4. Nanoparticle tracking analysis
for isolated exosome samples. A. Former
NanoSight NS300 findings to quantitate the
isolated exosomes in MeSOV and OVSAHO
cell lines treated with TEXi1.
Figure 2. OVCAR-4-CD63-Nluc model and determining IC50 concentrations for drug treatments. A. OVCAR-
4-CD63-Nluc model containing green luminescence protein on plasmid. B. MTS cell viability assay validating
OVCAR-4-CD63-Nluc model compared with OVCAR-4 and OVCAR-4-GFP serving as controls to verify exosome
concentration. C, D, E. Model used to treat cell lines with drugs GW4869, TEXi1, and TEXi2 at fixed time points (24,
48, and 72 hours) to determine IC50 values. MKT-077 and Nexinhib20 IC50 values calculated as 0.53 µM and 0.99
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